Skip to content
Inciteful Med

Understanding Alpha-1 Antitrypsin Deficiency (AATD)

Last updated:

Alpha-1 Antitrypsin Deficiency (AATD) is an inherited condition that reduces the body's protective proteins, leaving the lungs vulnerable to early-onset COPD and the liver prone to scarring. Early diagnosis, quitting smoking, and treatment can help protect your organs.

Key Takeaways

  • • Alpha-1 Antitrypsin Deficiency is a common but highly underdiagnosed genetic condition affecting the lungs and liver.
  • • A lack of functional AAT protein leaves the lungs vulnerable to tissue damage, which can lead to early-onset emphysema or COPD.
  • • In some types of AATD, misfolded proteins build up in the liver and cause inflammation, scarring, or prolonged jaundice in infants.
  • • Avoiding tobacco smoke and environmental pollutants is the single most important action to protect lung function.
  • • Augmentation therapy can help replace the missing AAT protein in the blood to slow down lung disease progression.

Receiving a diagnosis of Alpha-1 Antitrypsin Deficiency (AATD) often brings a mix of relief and concern. For many, this news comes after years of navigating unexplained respiratory or liver symptoms [1][2]. It is important to know that you are not alone; while once considered rare, AATD is one of the most common serious genetic conditions in the world [3][4].

What is Alpha-1?

Alpha-1 Antitrypsin Deficiency (AATD) is an inherited condition caused by mutations in the SERPINA1 gene [3]. This gene provides instructions for making the alpha-1 antitrypsin (AAT) protein, which is produced primarily in the liver [5][6].

In a healthy body, this protein travels through the bloodstream to the lungs. Its primary job is to act as a “protease inhibitor,” specifically neutralizing an enzyme called neutrophil elastase [7][8]. While neutrophil elastase helps fight infections, it can also digest healthy lung tissue if left unchecked [7][9]. In people with AATD, the protein is either not produced enough or is shaped incorrectly, leaving the lungs vulnerable [3][10].

How Common is It?

AATD affects approximately 1 in 1,600 to 1 in 2,000 live births in certain populations [1][4]. Despite this, it remains significantly underdiagnosed. Research suggests that up to 90% of individuals with the most severe form of the deficiency may not know they have it [1][4].

A Two-Part Disease Mechanism

AATD is unique because it affects the body through two distinct biological pathways:

  1. Lung Disease (Loss-of-Function): Because there isn’t enough functional AAT protein reaching the lungs, the “braking system” for inflammatory enzymes is lost [5][6]. This results in the gradual breakdown of the tiny air sacs in the lungs (alveoli), which can lead to early-onset emphysema or COPD (Chronic Obstructive Pulmonary Disease) [9][11][12].
  2. Liver Disease (Gain-of-Toxic-Function): In some types of AATD (most commonly the PiZZ genotype), the liver produces a “misfolded” version of the protein [13][14]. These malformed proteins get stuck inside the liver cells (hepatocytes) and form clumps [5][15]. This “gain of toxic function” can cause inflammation, scarring (cirrhosis), or liver failure over time [13][14]. In children, AATD liver involvement can also present early in infancy as prolonged neonatal jaundice [16].

Stabilizing Facts for the Newly Diagnosed

While a chronic diagnosis is life-changing, several key facts can provide a foundation for moving forward:

  • Knowledge is Protective: Early detection is a powerful tool. Knowing you have AATD allows you to make specific lifestyle choices that can significantly slow the progression of the disease [2][1].
  • Smoking Cessation is Vital: For those with lung involvement, the single most important action is avoiding tobacco smoke and environmental pollutants [17][10]. Smoking drastically accelerates lung damage in “Alphas” [18][19].
  • Treatment Options Exist: Augmentation therapy—a weekly intravenous infusion of AAT protein from healthy donors—can help raise the protein levels in your blood and slow the loss of lung tissue [1][20][21].
  • Family Testing: Since AATD is genetic, your diagnosis provides a “roadmap” for your relatives. Testing first-degree relatives (parents, siblings, and children) is the most efficient way to ensure they also receive the care they may need [22][23].
  • Focus on the Future: Many people with AATD live full, active lives by managing their environment, staying physically active, and working closely with a specialist [24][25].

Navigating This Guide

To help you understand your diagnosis, manage your condition, and build your care team, we have created the following resources:

Frequently Asked Questions

What causes Alpha-1 Antitrypsin Deficiency?
AATD is caused by inherited mutations in the SERPINA1 gene. This gene provides instructions for making the alpha-1 antitrypsin protein, which normally protects your tissues from inflammation.
How does AATD affect the lungs and liver?
In the lungs, a lack of protective AAT protein allows natural enzymes to damage healthy tissue, which can lead to early-onset emphysema or COPD. In the liver, abnormally shaped proteins can build up and cause inflammation or cirrhosis.
What is augmentation therapy for AATD?
Augmentation therapy is a weekly intravenous infusion of alpha-1 protein from healthy donors. This treatment helps raise the protective protein levels in your blood, which can slow the loss of healthy lung tissue.
Should my family members be tested for Alpha-1?
Yes, because AATD is an inherited condition, testing first-degree relatives like parents, siblings, and children is highly recommended. Early testing ensures your family members can receive proactive monitoring and care if they have the gene mutation.
Why is quitting smoking so important if I have AATD?
Smoking drastically accelerates lung damage in people with Alpha-1. Because your lungs already lack their natural defense system, avoiding tobacco smoke and environmental pollutants is the most vital step to protect your breathing.

Questions for Your Doctor

  • • What is my specific genotype (e.g., PiZZ, PiSZ, PiMZ) and what does it mean for my risk levels?
  • • What are my current alpha-1 antitrypsin (AAT) blood levels and my latest lung function (FEV1) results?
  • • Should I have a FibroScan or other tests to check my liver health, even if I don't have symptoms?
  • • Based on my current health, am I a candidate for augmentation therapy?
  • • Can you help me set up a screening plan for my children, siblings, or parents?

Questions for You

  • • How many years did it take from my first symptoms to getting this diagnosis?
  • • Am I still smoking or exposed to secondhand smoke, dust, or chemicals in my daily life?
  • • Have any of my blood relatives had unexplained lung or liver issues?
  • • What are my biggest concerns or priorities right now: managing symptoms, genetic risks for my family, or understanding treatment?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Alpha-1 antitrypsin deficiency: outstanding questions and future directions.

    Torres-Durán M, Lopez-Campos JL, Barrecheguren M, et al.

    Orphanet journal of rare diseases 2018; (13(1)):114 doi:10.1186/s13023-018-0856-9.

    PMID: 29996870
  2. 2

    The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency.

    Lascano JE, Campos MA

    Postgraduate medicine 2017; (129(8)):889-895 doi:10.1080/00325481.2017.1381539.

    PMID: 28929906
  3. 3

    Future Perspectives in the Diagnosis and Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency.

    Abreu N, Pereira VM, Pestana M, Jasmins L

    GE Portuguese journal of gastroenterology 2023; (30(5)):327-335 doi:10.1159/000528809.

    PMID: 37868641
  4. 4

    Portuguese consensus document for the management of alpha-1-antitrypsin deficiency.

    Lopes AP, Mineiro MA, Costa F, et al.

    Pulmonology 2018; (24 Suppl 1()):1-21 doi:10.1016/j.pulmoe.2018.09.004.

    PMID: 30473034
  5. 5

    Known Mutations at the Cause of Alpha-1 Antitrypsin Deficiency an Updated Overview of SERPINA1 Variation Spectrum.

    Seixas S, Marques PI

    The application of clinical genetics 2021; (14()):173-194 doi:10.2147/TACG.S257511.

    PMID: 33790624
  6. 6

    The Role of Neutrophils in Alpha-1 Antitrypsin Deficiency.

    McCarthy C, Reeves EP, McElvaney NG

    Annals of the American Thoracic Society 2016; (13 Suppl 4()):S297-304 doi:10.1513/AnnalsATS.201509-634KV.

    PMID: 27564664
  7. 7

    Post-Translational Modifications of Circulating Alpha-1-Antitrypsin Protein.

    Lechowicz U, Rudzinski S, Jezela-Stanek A, et al.

    International journal of molecular sciences 2020; (21(23)) doi:10.3390/ijms21239187.

    PMID: 33276468
  8. 8

    Alpha-1 antitrypsin in autoimmune diseases: Roles and therapeutic prospects.

    Sun R, Xu Z, Zhu C, et al.

    International immunopharmacology 2022; (110()):109001 doi:10.1016/j.intimp.2022.109001.

    PMID: 35803133
  9. 9

    Alpha-1 Antitrypsin Therapy in Cystic Fibrosis and the Lung Disease Associated with Alpha-1 Antitrypsin Deficiency.

    McElvaney NG

    Annals of the American Thoracic Society 2016; (13 Suppl 2()):S191-6 doi:10.1513/AnnalsATS.201504-245KV.

    PMID: 27115956
  10. 10

    Pulmonary manifestations of alpha 1 antitrypsin deficiency.

    Mulkareddy V, Roman J

    The American journal of the medical sciences 2024; (368(1)):1-8 doi:10.1016/j.amjms.2024.04.002.

    PMID: 38599244
  11. 11

    Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency-Related Lung Disease.

    Stiles KM, Sondhi D, Kaminsky SM, et al.

    Chronic obstructive pulmonary diseases (Miami, Fla.) 2018; (5(4)):244-257 doi:10.15326/jcopdf.5.4.2017.0160.

    PMID: 30723782
  12. 12

    Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.

    Rahaghi FF, Miravitlles M

    Respiratory research 2017; (18(1)):105 doi:10.1186/s12931-017-0574-1.

    PMID: 28558837
  13. 13

    The Mechanism of Mitochondrial Injury in Alpha-1 Antitrypsin Deficiency Mediated Liver Disease.

    Khodayari N, Wang RL, Oshins R, et al.

    International journal of molecular sciences 2021; (22(24)) doi:10.3390/ijms222413255.

    PMID: 34948056
  14. 14

    Erdj3 Has an Essential Role for Z Variant Alpha-1-Antitrypsin Degradation.

    Khodayari N, Marek G, Lu Y, et al.

    Journal of cellular biochemistry 2017; (118(10)):3090-3101 doi:10.1002/jcb.26069.

    PMID: 28419579
  15. 15

    Patient-Derived Induced Pluripotent Stem Cells for Alpha-1 Antitrypsin Deficiency Disease Modeling and Therapeutic Discovery.

    Kaserman JE, Wilson AA

    Chronic obstructive pulmonary diseases (Miami, Fla.) 2018; (5(4)):258-266 doi:10.15326/jcopdf.5.4.2017.0179.

    PMID: 30723783
  16. 16

    Liver Involvement in Children with Alpha-1 Antitrypsin Deficiency: A Multicenter Study.

    Cakir M, Sag E, Islek A, et al.

    Pediatric gastroenterology, hepatology & nutrition 2020; (23(2)):146-153 doi:10.5223/pghn.2020.23.2.146.

    PMID: 32206627
  17. 17

    Recurrence of emphysema post-lung transplantation in a patient with alpha 1 antitrypsin deficiency (AATD).

    Ataya A

    Respiratory medicine case reports 2020; (31()):101309 doi:10.1016/j.rmcr.2020.101309.

    PMID: 33304809
  18. 18

    [Alpha 1-antitrypsin deficiency].

    Mornex JF

    Revue des maladies respiratoires 2022; (39(8)):698-707 doi:10.1016/j.rmr.2022.02.062.

    PMID: 35715315
  19. 19

    Cigarette smoke exposed airway epithelial cell-derived EVs promote pro-inflammatory macrophage activation in alpha-1 antitrypsin deficiency.

    Khodayari N, Oshins R, Mehrad B, et al.

    Respiratory research 2022; (23(1)):232 doi:10.1186/s12931-022-02161-z.

    PMID: 36068572
  20. 20

    Alpha-1-Antitrypsin Deficiency: Disease Management and Learning from Studies.

    Greulich T

    COPD 2017; (14(sup1)):S8-S11 doi:10.1080/15412555.2017.1286166.

    PMID: 28306355
  21. 21

    Alpha-1 Antitrypsin Deficiency: Current Landscape of Detection, Management, and Treatment.

    Mawani R, Pye A, Turner AM

    Advances in therapy 2026; doi:10.1007/s12325-026-03496-5.

    PMID: 41678135
  22. 22

    The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.

    Sandhaus RA, Turino G, Brantly ML, et al.

    Chronic obstructive pulmonary diseases (Miami, Fla.) 2016; (3(3)):668-682 doi:10.15326/jcopdf.3.3.2015.0182.

    PMID: 28848891
  23. 23

    Detection of alpha-1 antitrypsin deficiency: the past, present and future.

    Brantly M, Campos M, Davis AM, et al.

    Orphanet journal of rare diseases 2020; (15(1)):96 doi:10.1186/s13023-020-01352-5.

    PMID: 32306990
  24. 24

    Alpha-1 antitripsyn deficiency and augmentation therapy in pregnancy: two case reports.

    Annunziata A, Fiorentino G, Coppola A, et al.

    Frontiers in medicine 2024; (11()):1479877 doi:10.3389/fmed.2024.1479877.

    PMID: 39736979
  25. 25

    Alpha 1-antitrypsin deficiency in patients with chronic obstructive pulmonary disease patients: is systematic screening necessary?

    da Costa CH, Noronha Filho AJ, Marques E Silva RMF, et al.

    BMC research notes 2019; (12(1)):10 doi:10.1186/s13104-018-4043-9.

    PMID: 30630519

This page provides an educational overview of Alpha-1 Antitrypsin Deficiency (AATD). It is for informational purposes only and does not replace professional medical advice from your pulmonologist, hepatologist, or genetic counselor.

Stay up to date

Get notified when new research about Alpha-1-antitrypsin deficiency is published.

No spam. Unsubscribe anytime.